{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:23:58Z","timestamp":1777944238835,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize the trends of psychotropic utilization before and after the formulary removal of melatonin in Alberta, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective drug utilization review of patients admitted to inpatient, long-term care, and pediatric units who received psychotropics for insomnia treatment. Utilization patterns were compared between two periods; pre-removal: January to December 2023 and post-removal: October 2024 to March 2025. Data were analyzed using defined daily dose per 1000 patient-days (DDD\/1000PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 101 pre-removal and 115 post-removal sites were included. There was a 13.5% relative decrease in psychotropic use, from 731.83 to 632.78 DDD\/1000PD. Melatonin use decreased from 95.60 to 13.94 DDD\/1000PD. In the post-removal period, the psychotropic classes with the highest utilization rates were benzodiazepines (203.26 DDD\/1000PD), Z-drugs (167.78 DDD\/1000PD), and antidepressants (148.75 DDD\/1000PD). The overall use of antidepressants increased by 17.3% while Z-drugs and benzodiazepines decreased by 8.8% and 8.4%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The temporal trends of psychotropics varied among zones, sites, and years within the same site. Overall, there was a decrease in psychotropic utilization, largely driven by decreases in the use of Z-drugs and benzodiazepines. The findings should be interpreted with caution, as results may not be generalizable to other institutions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10398562261446491","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:47:59Z","timestamp":1777434479000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of delisting melatonin from a health-system formulary on psychotropic utilization"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9275-8567","authenticated-orcid":false,"given":"Ryan R. D.","family":"Chan","sequence":"first","affiliation":[{"name":"Alberta Health Services"},{"name":"University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Nickonchuk","sequence":"additional","affiliation":[{"name":"Alberta Health Services"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rekha","family":"Jabbal","sequence":"additional","affiliation":[{"name":"Alberta Health Services"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Cheng","sequence":"additional","affiliation":[{"name":"Alberta Health Services"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micheal","family":"Guirguis","sequence":"additional","affiliation":[{"name":"Alberta Health Services"},{"name":"University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.12.023"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzae042"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepx.2022.100059"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-024-03144-8"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S134864"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010256"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2019.05.006"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.8986"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211017857"},{"issue":"5","key":"e_1_3_5_11_2","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline","volume":"64","author":"Pottie K","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician 2018; 64(5): 339\u2013351.","journal-title":"Can Fam Physician"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09065-2"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004690"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-022-02409-5"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1998"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/jicm.2023.0170"},{"key":"e_1_3_5_17_2","unstructured":"ATC\/DDD Index. Norwegian institute of public health WHO collaborating centre for drug statistics methodology. 2025. Available from: https:\/\/atcddd.fhi.no\/atc\/structure_and_principles\/"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102507"},{"key":"e_1_3_5_19_2","volume-title":"Census Profile, 2021 Census of Population of Alberta","year":"2025","unstructured":"Census Profile, 2021 Census of Population of Alberta. Canada: Statistics Canada; 2025. Available from: https:\/\/www12.statcan.gc.ca\/census-recensement\/2021\/dp-pd\/prof\/index.cfm?Lang=E"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-016-0080-7"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-0361.2012.00428.x"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1715163520929734"},{"key":"e_1_3_5_23_2","first-page":"195","volume-title":"RxFiles Drug Comparison Charts. University of Saskatchewan, Saskatoon (SK)","author":"Regier L","year":"2025","unstructured":"Regier L, Jensen B, Soubolsky A. Sleep disorders: overview. In: RxFiles Drug Comparison Charts. University of Saskatchewan, Saskatoon (SK). RxFiles Academic Detailing, 2025, pp. 195\u2013196."},{"key":"e_1_3_5_24_2","volume-title":"Canadians report increasing need for mental health care alongside barriers to access","year":"2024","unstructured":"Canadians report increasing need for mental health care alongside barriers to access. Canadian Institute for Health Information; 2024. Available from: https:\/\/www.cihi.ca\/en\/canadians-report-increasing-need-for-mental-health-care-alongside-barriers-to-access"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70059"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12594"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6470"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01616-7"}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562261446491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10398562261446491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562261446491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:51:05Z","timestamp":1777708265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10398562261446491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":27,"alternative-id":["10.1177\/10398562261446491"],"URL":"https:\/\/doi.org\/10.1177\/10398562261446491","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"10398562261446491"}}